XY
Therapeutic Areas
Akeso Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Cadonilimab (AK104) | Recurrent/Metastatic Cervical Cancer | Approved |
| Ivonescimab (AK112) | EGFR-TKI Failed nsq-NSCLC | Approved |
| Penpulimab (AK105) | r/r cHL, sq-NSCLC, NPC | Approved |
| Inusiran (AK102) | Hypercholesterolemia | Approved |
| Iruxolimab (AK101) | Moderate-to-Severe Plaque Psoriasis | Approved |
| AK129 | Advanced Solid Tumors | Phase I/II |
| AK131 | Advanced Solid Tumors | Phase I |
| AK130 | Advanced Solid Tumors | Phase I |
Leadership Team at Akeso
LB
Li Baiyong
Co-Founder, Executive VP & Chief Scientific Officer
WZ
Wang Zhongmin
Co-Founder, Senior VP
ZP
Zhang Peng
Co-Founder, Senior VP
XY
Xia Yu (Xia Yu)
Senior VP
WB
Wang Bingzhong
Chief Financial Officer
GY
Guo Yong
Chief Commercial Officer & Senior VP
HM
Hu Mingxiu
Senior VP
ZX
Zhang Xinfeng
Senior VP
MJ
Min Jing
Senior VP